This is the most consequential trade action to hit the pharmaceutical industry in modern history. President Trump signed a Section 232 proclamation on April 2 imposing 100% ad valorem tariffs on imported patented pharmaceutical products and active pharmaceutical ingredients, effective July 31 for 17 large companies and September 29 for everyone else. But the structure is not designed to punish—it is designed to reward cooperation. Companies that have signed Most Favored Nation pricing agreements with HHS and committed to U.S. onshoring pay nothing. Companies building domestic manufacturing pay 20%. Companies that have done neither face the full 100%. Generics and biosimilars are entirely exempt. Thirteen companies already have qualifying agreements in place. The practical impact on large pharma companies that engaged with the administration early will be manageable. The companies exposed are mid-sized biotechs importing patented products without MFN agreements. And buried in the same White House fact sheet: active Section 232 investigations into medical devices, PPE, and medical consumables. Medtech is next. Orforglipron is 4 days away.
Top Story: The Section 232 Pharmaceutical Tariff Framework
What Happened: President Trump signed a proclamation imposing 100% ad valorem tariffs on imported patented pharmaceutical products and active pharmaceutical ingredients under Section 232 of the Trade Expansion Act of 1962. The Commerce Department investigation, initiated April 1, 2025, found that approximately 53% of patented pharmaceutical products and 85% of patented APIs (by volume) are produced outside the United States, constituting a national security threat under the statute.
The Tiered Structure: Cooperation Pays, Resistance Costs
The tariff framework is not a blunt instrument. It is a tiered system that explicitly rewards companies for engaging with the administration on pricing and manufacturing:
100% tariff (baseline): For companies that have not negotiated onshoring or MFN pricing agreements. Effective July 31 for 17 large companies listed in Annex III, and September 29 for all other companies.
20% tariff: For companies with Commerce-approved plans to onshore pharmaceutical production to the United States. This rate escalates to 100% after four years (April 2, 2030) if onshoring is not completed.
0% tariff: For companies with both approved onshoring plans and MFN pricing agreements with HHS. This exemption lasts through January 20, 2029. Thirteen companies already have qualifying agreements.
15% tariff: For products from the EU, Japan, South Korea, Switzerland, and Liechtenstein under existing bilateral trade agreements.
0% tariff (U.K.): Under a new pharmaceutical agreement finalized the same day, U.K. drug exports enter the U.S. tariff-free through at least January 2029.
Exempt: Generic pharmaceuticals, biosimilar products, and their associated ingredients. The Commerce Secretary will reassess this exemption in one year.
Exempt (specialty): Orphan drugs, cell and gene therapies, plasma-derived therapies, nuclear medicines, antibody drug conjugates, fertility treatments, and medical countermeasures qualify for 0% if from trade deal countries or meeting urgent public health needs.
Understanding the Dual-Leverage Strategy
The tiered structure reveals what the administration is actually trying to accomplish. This is not primarily a revenue-generating tariff. It is a leverage mechanism designed to achieve two separate policy goals simultaneously.
The first goal is lower drug prices, achieved through MFN agreements with HHS that commit companies to offering U.S. prices at or near the lowest prices they charge in other developed markets. The second goal is domestic manufacturing, achieved through onshoring agreements with Commerce that commit companies to building or expanding pharmaceutical production facilities in the United States. Companies that give the administration both concessions pay 0%. Companies that give neither face 100%.
The White House cited approximately $400 billion in new U.S. pharmaceutical manufacturing investment commitments that it attributes to the Section 232 threat. Whether that investment materializes at the promised scale is a separate question, but the political narrative is already established: tariff threats produced hundreds of billions in reshoring commitments.
RBC Capital Markets took a measured view of the practical impact, writing that the announcement “removes a policy overhang” and that “almost every major drugmaker cooperated.” For the 13 companies with existing MFN and onshoring agreements, the tariffs change nothing operationally—these companies were already paying 0% under the negotiated framework and will continue to do so.
Who Is Protected
The large-cap pharmaceutical companies that engaged with the administration early are fully insulated. Pfizer, Eli Lilly, Novo Nordisk, AstraZeneca, Johnson & Johnson, Merck, and others that signed MFN pricing agreements and committed to U.S. manufacturing investments face a 0% effective tariff rate through January 2029. These companies made the calculation that voluntary pricing concessions and manufacturing commitments were preferable to an uncertain tariff environment—and that calculation proved correct.
The generic and biosimilar exemption is strategically significant. By exempting generics entirely, the administration avoids a political crisis around drug costs for the most price-sensitive patient populations. The one-year reassessment window keeps generic manufacturers aware that the exemption is not permanent, maintaining leverage without triggering immediate supply disruption.
The specialty exemptions—orphan drugs, cell and gene therapies, plasma-derived therapies, ADCs, and others—protect therapeutic categories where supply disruption could directly endanger patients. These carveouts reflect an awareness that certain product categories cannot be rapidly reshored without risking critical shortages.
Who Is Exposed
The companies facing real economic impact are mid-sized biotechs that import patented products manufactured overseas, have not signed MFN pricing agreements with HHS, and lack the capital or infrastructure to commit to U.S. onshoring. For these companies, the 100% tariff effective September 29 could fundamentally alter product economics. A drug manufactured in Ireland or Switzerland and imported for U.S. sale would see its landed cost double overnight.
The Mid-Sized Biotech Alliance of America has already begun lobbying against the tariffs. BIO President John Crowley warned that “tariffs on America’s medicines will raise costs, impede domestic manufacturing, and delay the development of new treatments.” PhRMA also opposed the action. Legal challenges are considered probable, particularly from companies arguing that Section 232’s national security rationale does not legitimately apply to pharmaceutical imports.
The January 2029 Sunset: The Detail That Matters Most
The 0% tariff rate for companies with MFN and onshoring agreements expires January 20, 2029—the last day of the current presidential term. This date is not coincidental. Any future administration could renegotiate, extend, or terminate these agreements entirely.
For pharmaceutical companies making 10-year manufacturing investment decisions based on the current framework, the sunset creates significant planning uncertainty. A factory that takes three years to build and begins production in 2029 could face an entirely different tariff regime by the time it reaches commercial-scale output. The administration has created powerful near-term incentives for onshoring, but the long-term durability of those incentives depends on political continuity that no company can guarantee.
The Bilateral Trade Agreements
The reduced tariff rates for allied countries reflect a parallel diplomatic track. The EU, Japan, South Korea, and Switzerland face a 15% tariff under existing trade agreements—substantially lower than the 100% baseline but not zero. The United Kingdom secured a full exemption under a new bilateral pharmaceutical agreement finalized the same day as the proclamation.
These tiered country rates create competitive dynamics among manufacturing locations. Companies deciding where to build new capacity will weigh the 0% U.S. domestic rate against the 15% allied-country rate against the 100% baseline for non-treaty countries. The framework explicitly incentivizes U.S. domestic production over all alternatives, with allied-country manufacturing as a preferred second option.
Our Pro brief includes a full analysis of which specific companies face the most tariff exposure, how the MFN pricing agreements function as leverage rather than revenue policy, and the strategic playbook for mid-sized biotechs navigating the September 29 deadline. [Details below.]
What to Watch
The immediate catalyst is whether the tariff announcement triggers a wave of mid-sized biotech companies rushing to negotiate MFN and onshoring agreements with Commerce and HHS before the September 29 deadline. Legal challenges from industry groups are probable and could delay implementation. The generic and biosimilar exemption reassessment in one year will determine whether the protected status for these categories is permanent or temporary. And the January 2029 sunset on the 0% rate creates a political risk overlay that will influence every major pharmaceutical manufacturing decision made in the next three years.
Medical Devices Are Next: Active Section 232 Investigation
What’s Happening: The White House fact sheet accompanying the pharmaceutical tariffs explicitly referenced “Section 232 investigations in adjacent sectors such as personal protective equipment, medical consumables, and medical equipment and devices.” The Commerce Department initiated this investigation on September 2, 2025, covering surgical masks, syringes, catheters, pacemakers, insulin pumps, blood glucose monitors, imaging machines, and wheelchairs, among other products.
The Timeline
The Commerce Department has 270 days from initiation to deliver a report to the president, placing the deadline around late May 2026. After that, the president has 90 days to act. William Blair analyst Brandon Vazquez projected the earliest any action would go into effect is summer 2026. Needham analyst Mike Matson wrote that he expects the investigation to “eventually result in additional tariffs for the industry.”
What the Pharma Precedent Tells Medtech Companies
The pharmaceutical tariff structure offers a near-certain template for how medical device tariffs will be designed. The pattern is now established: investigate, threaten a high baseline rate, negotiate bilateral agreements and onshoring commitments, then implement with favorable treatment for cooperators.
Medtech has a stronger domestic manufacturing argument than pharma. AdvaMed CEO Scott Whitaker emphasized that 70% of medical equipment used in the U.S. is domestically manufactured, which should support a case for more limited tariff scope. However, the domestic production percentage varies dramatically by product category. Imaging equipment has significant foreign manufacturing concentration—Siemens Healthineers and Philips are major non-U.S. producers—while surgical devices and orthopedic implants are more heavily produced domestically.
The companies that proactively engage with Commerce on onshoring plans before the report is issued will be best positioned. The pharmaceutical precedent makes this clear: early cooperators received the most favorable treatment, and companies that waited faced the harshest terms.
Our Pro brief maps the medtech tariff playbook based on the pharma precedent, identifies which device categories face the most import concentration risk, and assesses AdvaMed’s lobbying position. [Details below.]
Strategic Themes
1. The Tariff Structure Is Leverage, Not Protectionism
The 100% headline number is designed to generate compliance, not revenue. The tiered framework—0% for full cooperators, 20% for partial cooperators, 100% for holdouts—reveals an administration that is using trade policy as a negotiating tool to achieve pricing concessions and manufacturing commitments simultaneously. For the large-cap companies that engaged early, the practical impact is negligible. The tariffs function as a reward for cooperation rather than a punishment for importing.
2. Mid-Sized Biotech Faces a September Deadline and Limited Options
The companies most affected by the tariffs are mid-sized biotechs that import patented products without MFN agreements. These companies often lack the capital to commit to U.S. manufacturing and the negotiating leverage to secure favorable MFN terms. The September 29 deadline creates genuine urgency—a 100% tariff on imported product could make entire commercial models economically unviable. Expect a wave of smaller companies seeking MFN agreements, onshoring commitments, or legal challenges in the coming months.
3. Medtech Should Be Preparing Now, Not Waiting
The pharmaceutical tariff announcement included explicit references to active Section 232 investigations into medical devices. The Commerce Department report is due by late May, with presidential action possible by summer. Medtech companies that wait for the report before engaging with Commerce are making the same mistake that pharma companies who waited until the last minute now regret. The precedent is clear: engage early, commit to domestic manufacturing where feasible, and negotiate for the most favorable tier before the final structure is announced.
4. Orforglipron Arrives in 4 Days Against a Reshaped Policy Backdrop
The April 10 target action date for Lilly’s oral GLP-1 now carries additional strategic significance beyond clinical and commercial considerations. Lilly has committed to massive U.S. manufacturing expansion—including the LillyPod AI factory, new production facilities in Indiana, and supply chain investments that position the company for favorable tariff treatment. An orforglipron approval would add the most commercially significant new product launch of the year to a company that is already among the best-positioned under the new tariff framework. The intersection of trade policy and product launches creates a uniquely favorable environment for Lilly specifically.
Frequently Asked Questions
What exactly did the Section 232 proclamation do?
President Trump imposed 100% tariffs on imported patented pharmaceutical products and active pharmaceutical ingredients. The tariffs are tiered: companies with MFN pricing agreements and onshoring plans pay 0%, companies with onshoring plans only pay 20%, and companies without either pay the full 100%. Generics and biosimilars are entirely exempt. Products from the EU, Japan, South Korea, and Switzerland face 15% under trade agreements. U.K. exports are tariff-free.
Which companies are protected?
The 13 companies with existing MFN pricing and onshoring agreements pay 0% through January 2029. These are primarily large-cap pharmaceutical companies that engaged with the administration early, including Pfizer, Lilly, Novo Nordisk, AstraZeneca, and others. RBC Capital Markets noted that “almost every major drugmaker cooperated.”
Which companies are most exposed?
Mid-sized biotechs that import patented products manufactured overseas without MFN agreements face the full 100% tariff starting September 29. These companies often lack the capital for U.S. onshoring commitments and the negotiating leverage for favorable MFN terms. The Mid-Sized Biotech Alliance of America is already lobbying against the tariffs.
Why are generics and biosimilars exempt?
Exempting generics avoids a political crisis around drug costs for the most price-sensitive patients and the government programs (Medicare, Medicaid) that depend on affordable generic supply. The one-year reassessment window maintains leverage over generic manufacturers without triggering immediate disruption.
What does the January 2029 sunset mean?
The 0% tariff rate for cooperating companies expires on the last day of the current presidential term. Any future administration could change the terms. This creates planning uncertainty for companies making long-term manufacturing investment decisions based on the current framework.
Are medical device tariffs coming?
Almost certainly. The White House fact sheet referenced active Section 232 investigations into medical equipment, PPE, and medical consumables. The Commerce Department report is expected by late May 2026, with presidential action possible by summer. The pharmaceutical tariff structure will likely serve as the template for device tariff design.
How does this affect orforglipron’s approval on April 10?
Directly, it does not—FDA approval decisions are independent of trade policy. Strategically, Lilly’s extensive U.S. manufacturing commitments position the company favorably under the tariff framework. Lilly has stockpiled $1.5 billion worth of orforglipron for launch readiness, and its domestic production infrastructure qualifies for the most favorable tariff treatment.
Will there be legal challenges?
Probable. Industry groups and individual companies may challenge whether Section 232’s national security rationale legitimately applies to pharmaceutical imports. PhRMA and BIO both opposed the tariffs. The legal timeline could take months to years, but challenges are unlikely to delay the July 31 effective date for the 17 large companies listed in Annex III.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Section 232 Deep Dive: Who’s Protected, Who’s Exposed. We map every major pharma company against the tiered tariff structure, identify which mid-sized biotechs face the most economic risk from the September 29 deadline, and analyze the specialty exemption categories that protect orphan drugs, gene therapies, and ADCs.
The MFN Pricing Leverage Play. We break down how the administration is using tariffs to force both pricing concessions and onshoring commitments simultaneously, assess whether the $400 billion in investment commitments is credible, and model the January 2029 sunset risk for companies making decade-long manufacturing decisions.
MedTech Tariff Playbook. The pharma precedent tells you exactly how device tariffs will be structured. We map which device categories face the most import concentration risk, assess AdvaMed’s lobbying position, and identify the companies that should be engaging with Commerce now rather than waiting for the report.
Plus: Orforglipron 4-day countdown, the tariff framework’s implications for Lilly’s launch economics, and the updated catalyst calendar through mid-2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
